Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

In the United Kingdom, a 13-year-old patient with acute lymphoblastic leukemia participated in a clinical trial for an experimental treatment using base-edited chimeric antigen receptor (CAR) T-cells, and is now in remission. Researchers presented findings from the study at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, this past weekend. (UK Research and Innovation)

Meanwhile, to launch the ASH meeting in New Orleans, Nicole Gormley, M.D., acting director of the Division of Hematology Products at FDA, spoke of the need to continue the momentum of decentralized clinical trials brought about by the global COVID-19 pandemic. (AJMC)

Neurologylive spoke with the CEO of Linus Health, David Bates, Ph.D., to discuss the potential new Alzheimer's treatment, lecanemab, and how technology can advance Alzheimer's clinical trials.

‍

‍
‍

Our Culture

“We are small enough that we are nimble, so we can prioritize quickly, yet also of significant size that we allocate resources where needed. We truly do a lot. This is my dream job. Judi allows me to have a bigger impact. And we do great work.”

   –Jess, Program Manager

‍‍
‍

About Judi

Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

‍

‍

‍

‍